Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Bystin is a highly conserved, non-enzymatic protein encoded by the BYSL gene. It plays a dual role in mammalian cellular physiology: as an **essential ribosome biogenesis factor**, it facilitates the maturation of the small (40S) ribosomal subunit by supporting proper processing of 18S rRNA, thus supporting rapid cell growth and protein synthesis in proliferative contexts such as embryonic tissues and cancers[2][4][6]. In parallel, bystin mediates **cell adhesion processes** crucial for embryo implantation by forming complexes with trophinin and tastin, stabilized further by cytokeratin interactions[1][5]. BYSL is localized to the nucleolus and cytoplasm, its expression is regulated by growth signals (including c-MYC), and is highly expressed in dividing cells. Knockdown or loss leads to severe defects in cell viability, nucleologenesis, and embryo development. BYSL is not a typical therapeutic target (receptor, enzyme, transporter), but may serve as a proliferation marker, especially in cancers, and as a molecular link between cell adhesion and ribosomal function[1][2][3][4][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Bystin (BYSL).